Carniford contains Levocarnitine. Carniford uses:
The supplemental Carniford use is widely established in the management of cardiac ischemia and peripheral arterial disease. It is generally indicated for cardio protection. It lowers triglyceride levels and increases levels of HDL cholesterol. It is used with benefits in those with primary and secondary carnitine deficiency syndromes. There is also evidence of its use in liver, kidney and immune disorders or in diabetes and Alzheimer's disease. There is little evidence that supplemental Carniford boosts energy, increases athletic performance or inhibits obesity. The indications of Carniford may be summarized as follows:
|Therapeutic Class:||Drugs for muscular energy metabolism|
|Manufacturer:||MAXFORD LABS PVT LTD|
|Last Updated:||2020-11-22 18:15:00|
Carniford contains Levocarnitine 500.0 Mg. Carniford doses
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.Syrup-
Generally Carniford is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur
Carniford is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production in the form of Adenosine Tri phosphate or ATP. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.
The safety and efficacy of oral Carniford has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral Carniford in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
Carniford is categorized by the USFDA as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Supplemental Carniford should be used by pregnant women only if clearly indicated and only under medical supervision. It is not known whether Carniford is excreted in human milk. Supplemental Carniford is not advised for nursing mothers. Those with seizure disorders should only use Carniford under medical advisement and supervision.
There is no known disease or syndrome in which Carniford administration is contraindicated. It is contraindicated in patients with hypersensitivity to any of its components.
There have been no reports of toxicity from levocarnitine overdosage. Carniford is easily removed from plasma by dialysis. The intravenous LD50 of levocarnitine in rats is 5.4 g/kg and the oral LD50 of levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea.
Tablet: Store in a cool & dry place, protected from light & moisture.
Solution: Store in a cool & dry place, protected from light.
Carniford Capsule price in India 153